The first studies aimed to co-deliver a sensitizing agent used already approved chemotherapeutics known to induce DR4/DR5 expression by triggering cellular stress thus sensitizing cancer cells to TRAIL, such as derivatives of the microtubule inhibitor, taxol and DNA damaging agents, such as doxorubicin and mitoxantrone [240,249]. This evidence concerns the gene TNFSF10 and cancer.